Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients on apixaban, dabigatran, rivaroxaban: cohorts comprising new initiators and/or switchers from warfarin

被引：0
|
作者：
Tepper, P. [1 ]
Mardekian, J. [2 ]
Masseria, C. [2 ]
Phatak, H. [3 ]
Kamble, S. [3 ]
Abdulsattar, Y. [2 ]
Petkun, W. [3 ]
Lip, G. Y. H. [4 ]
机构：
[1] Univ Pittsburgh, Epidemiol, Pittsburgh, PA USA
[2] Pfizer Inc, New York, NY USA
[3] Bristol Myers Squibb Co, Princeton, NJ USA
[4] Univ Birmingham, Birmingham, W Midlands, England
来源：
EUROPEAN HEART JOURNAL | 2015年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1975
引用
收藏
页码：339 / 339
页数：1
相关论文
共 50 条
  • [41] Value-based pricing for dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation in Germany
    Krejczy, Martin
    Marx, Svetlana
    Obermann, Konrad
    Wehling, Martin
    Harenberg, Job
    THROMBOSIS RESEARCH, 2012, 130 : S100 - S100
  • [42] Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries
    Krejczy, Martin
    Harenberg, Job
    Marx, Svetlana
    Obermann, Konrad
    Froelich, Lutz
    Wehling, Martin
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2014, 37 (04) : 507 - 523
  • [43] Effectiveness and safety of apixaban, dabigatran and warfarin compared to rivaroxaban in non-valvular atrial fibrillation; a Norwegian nationwide cohort study
    Rutherford, O. -C. W.
    Jonasson, C. J.
    Ghanima, W. G.
    Halvorsen, S. H.
    EUROPEAN HEART JOURNAL, 2019, 40 : 1846 - 1846
  • [44] Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries
    Martin Krejczy
    Job Harenberg
    Svetlana Marx
    Konrad Obermann
    Lutz Frölich
    Martin Wehling
    Journal of Thrombosis and Thrombolysis, 2014, 37 : 507 - 523
  • [45] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Carla Rognoni
    Monia Marchetti
    Silvana Quaglini
    Nicola Lucio Liberato
    Clinical Drug Investigation, 2014, 34 : 9 - 17
  • [46] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Rognoni, Carla
    Marchetti, Monia
    Quaglini, Silvana
    Liberato, Nicola Lucio
    CLINICAL DRUG INVESTIGATION, 2014, 34 (01) : 9 - 17
  • [47] Real-world adherence to warfarin, dabigatran, rivaroxaban, and apixaban among patient with nonvalvular atrial fibrillation: 2010-2015
    Pham, Phuong N.
    Brown, Joshua D.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 60 - 60
  • [48] Peripheral leukocyte count and risk of bleeding in patients with non-valvular atrial fibrillation taking dabigatran: a real-world study
    Zhou, Wei
    Wang, Tao
    Zhu, Ling-Juan
    Wen, Ming-Hua
    Hu, Li-Hua
    Huang, Xiao
    You, Chun-Jiao
    Li, Ju-Xiang
    Wu, Yan-Qing
    Wu, Qing-Hua
    Bao, Hui-Hui
    Cheng, Xiao-Shu
    CHINESE MEDICAL JOURNAL, 2019, 132 (18) : 2150 - 2156
  • [49] Peripheral leukocyte count and risk of bleeding in patients with non-valvular atrial fibrillation taking dabigatran: a real-world study
    Zhou Wei
    Wang Tao
    Zhu Ling-Juan
    Wen Ming-Hua
    Hu Li-Hua
    Huang Xiao
    You Chun-Jiao
    Li Ju-Xiang
    Wu Yan-Qing
    Wu Qing-Hua
    Bao Hui-Hui
    Cheng Xiao-Shu
    中华医学杂志英文版, 2019, 132 (18) : 2150 - 2156
  • [50] Dabigatran in 'real-world' clinical practice for stroke prevention in patients with non-valvular atrial fibrillation
    Potpara, Tatjana S.
    THROMBOSIS AND HAEMOSTASIS, 2015, 114 (06) : 1093 - 1098
12345